What one share of Tenaya Therapeutics holds
We are a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease.
Tenaya Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.53 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.27 |
| Cash and investments | $0.35 |
| Book value | $0.31 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$39.50 | $10.04 | −$46.51 | — | −$67.19 |
| 2021 | — | −$4.10 | $1.42 | −$4.85 | — | — |
| 2022 | — | −$2.76 | $0.46 | −$2.79 | — | $3.64 |
| 2023 | — | −$1.68 | $0.02 | −$1.40 | — | $2.04 |
| 2024 | — | −$1.31 | $0.01 | −$1.08 | — | $1.07 |
| 2025 | — | −$0.59 | $0.00 | −$0.45 | — | $0.57 |
Common questions about Tenaya Therapeutics
How much does one share of Tenaya Therapeutics earn?
Over the last 12 months, Tenaya Therapeutics lost $0.53 for each share.
Does Tenaya Therapeutics pay a dividend?
Tenaya Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Tenaya Therapeutics’s book value per share?
Tenaya Therapeutics’s book value is $0.31 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Tenaya Therapeutics have?
Each share of Tenaya Therapeutics has $0.35 of cash and investments, as of June 30, 2026.
What is Tenaya Therapeutics’s free cash flow per share?
−$0.27 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Tenaya Therapeutics bought back shares?
Tenaya Therapeutics’s share count rose about 15636% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.